Pharma channel feed

Black­stone's GRIN inks epilep­sy li­cens­ing deal with An­geli­ni, clos­es $140M Se­ries D

Last month
Deals

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

Last month

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

Last month
Manufacturing
Law

CHMP clears path for GSK’s Blenrep re­launch, rec­om­mends four oth­er drugs 

Last month
FDA+

Gilead notch­es an­oth­er Phase 3 win for Trodelvy in triple-neg­a­tive breast can­cer

Last month
R&D

GSK’s Nu­cala wins COPD ap­proval, stok­ing ri­val­ry with Dupix­ent 

Last month
FDA+

Roche con­firms over­all sur­vival ben­e­fit for PI3K in­hibitor in breast can­cer

Last month
R&D

Jazz out­lines full sur­vival da­ta for lung can­cer drug Zepzel­ca

Last month
R&D

House pass­es Trump tax bill with PBM and or­phan drug re­forms in­clud­ed

Last month
Law

Cigna, No­vo of­fer low­er GLP-1 prices to lure pa­tients to brand-name drugs

Last month
Health Tech

The ‘MA­HA re­port’: Four key take­aways on vac­cines, med­i­cine and the phar­ma in­dus­try

Last month
FDA+

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

Last month
Manufacturing

Sanofi makes $470M move for Vig­il's Alzheimer's drug, while an­oth­er as­set re­turns to Am­gen

Last month
Deals

FDA ad­comm votes unan­i­mous­ly against Pfiz­er's prostate can­cer drug com­bo

Last month
FDA+

FDA asks Covid vac­cine mak­ers to add more my­ocardi­tis da­ta to la­bels

Last month
FDA+

FDA an­nounces ef­forts to fa­cil­i­tate drug im­por­ta­tion from Cana­da 

Last month
FDA+
Manufacturing

Te­va, No­var­tis get fresh warn­ings from FTC over Or­ange Book patent list­ings

Last month
Law

FDA ad­comm nar­row­ly votes against Uro­Gen’s blad­der can­cer drug, calls for RCTs

Last month
FDA+

RFK Jr. spars with sen­a­tors over re­search cuts, HHS bud­get plan

Last month
FDA+

Up­dat­ed: Trump ad­min­is­tra­tion re­veals 'most fa­vored na­tion' drug price coun­try tar­gets

Last month
Law

Pfiz­er joins PD-1xVEGF race with $1.25B up­front to Chi­nese biotech 3SBio

Last month
Deals
China

Ste­lara biosim­i­lars look to gain trac­tion, helped by re­cent lessons from Hu­mi­ra

Last month

In­tel­li­a's CRISPR ther­a­py like­ly caus­es 'per­ma­nen­t' gene knock­down in AT­TR amy­loi­do­sis

Last month
R&D
Cell/Gene Tx

Re­gen­eron plans to buy 23andMe for $256M

Last month
Deals
First page Previous page 3456789 Next page Last page
A service from the Financial Times